MARKET

CLDX

CLDX

Celldex Therapeutics Inc
NASDAQ
27.16
+0.73
+2.76%
After Hours: 27.16 0 0.00% 17:41 12/31 EST
OPEN
26.34
PREV CLOSE
26.43
HIGH
27.65
LOW
25.90
VOLUME
722.47K
TURNOVER
--
52 WEEK HIGH
30.50
52 WEEK LOW
14.40
MARKET CAP
1.80B
P/E (TTM)
-8.0312
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CLDX last week (1222-1226)?
Weekly Report · 12/29/2025 09:51
First Week of CLDX August 2026 Options Trading
NASDAQ · 12/22/2025 15:43
Weekly Report: what happened at CLDX last week (1215-1219)?
Weekly Report · 12/22/2025 09:51
Celldex Therapeutics Is Maintained at Underweight by Barclays
Dow Jones · 12/17/2025 17:49
Celldex Therapeutics Price Target Raised to $24.00/Share From $21.00 by Barclays
Dow Jones · 12/17/2025 17:49
Barclays Maintains Underweight on Celldex Therapeutics, Raises Price Target to $24
Benzinga · 12/17/2025 17:38
Celldex (CLDX) Receives a Sell from Barclays
TipRanks · 12/17/2025 09:18
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga · 12/15/2025 13:06
More
About CLDX
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.

Webull offers Celldex Therapeutics Inc stock information, including NASDAQ: CLDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLDX stock methods without spending real money on the virtual paper trading platform.